Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

August 31, 2008

Conditions
Pancreatic Cancer
Interventions
BIOLOGICAL

bevacizumab

30-90 minutes on day 1, every 21 days up to 12 months.

DRUG

capecitabine

twice daily on days 1-14. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.

DRUG

gemcitabine hydrochloride

IV over 30 minutes on days 1 and 8. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.

Trial Locations (2)

14263-0001

Roswell Park Cancer Institute, Buffalo

44106-1714

Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER

NCT00100815 - Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter